PRITESH SHAH: Open Payments
NPI 1114121175 · WESTWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,269 in 71 payments from 13 companies in 2025. Trend: 2023 $801 · 2024 $719 · 2025 $1,269
Food & beverage: $1,269
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $255 |
| Neurocrine BioSciences, Inc. | 6 | $191 |
| Otsuka America Pharmaceutical, Inc. | 10 | $167 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 6 | $98 |
| E.R. Squibb & Sons, L.L.C. | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $76 |
| Alkermes, Inc. | 4 | $61 |
| Neos Therapeutics, LP | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
Products named: VRAYLAR, INGREZZA, REXULTI, TEZSPIRE, COBENFY, AUSTEDO XR, TRINTELLIX, HETLIOZ.
Industry payments across NJ — which companies pay providers there.
